Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2016

View Archived Issues

Allakos completes dosing in phase I trial of AK-001

FDA grants orphan drug designation to Thetis Pharmaceuticals' TP-252

Mifepristone granted .U.S orphan designation for ovarian cancer

Amarantus and Avant Diagnostics enter a letter of intent to merge diagnostics business unit

Primate models of retinal degeneration allow assessment of retinal transplantation

Glenmark updates pipeline data

Coprimary efficacy endpoints met in phase III trial of beloranib for Prader-Willi syndrome

Transgenomic launches new MX-ICP cancer panels

Novozymes forms an independent company to separate its biopharma activities

FDA approves sBLA for Arzerra as extended treatment of recurrent or progressive CLL

Enrollment open in phase I/II study of Cytori Cell Therapy

Novel stem cell therapy demonstrates preclinical efficacy in AD models

FDA grants breakthrough therapy designation for venetoclax in relapsed/refractory CLL

FDA approves Neulasta to treat radiation sickness

Launch of a new partnership focused on accelerating Alzheimer's treatment

Apatorsen misses PFS endpoint in phase II NSCLC trial

Sunshine Lake Pharma patents 5-HT6 receptor antagonists

Ensysce Biosciences and Signature Therapeutics complete merger

Spero Therapeutics describes antibacterials

Daiichi Sankyo develops LRS inhibitors

The University of Tokyo divulges P2Y10 agonists

Kuros Biosurgery Holding closes merger with Cytos Biotechnology

UAB Research Foundation reports retinoid RXR agonists

Cosentyx available in U.S. for treatment of ankylosing spondylitis and psoriatic arthritis

New sound wave technology may revolutionize nebulizers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Harbour Biomed closes busy year with $1B+ BMS deal
BioWorld
Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...